Technical standards and guidelines: Prenatal screening for Down syndrome

Genetics in Medicine

Volumn 7, Issue 5, 2005, Pages 344-354

  Palomaki, Glenn E ^a,b   Bradley, Linda A ^c   McDowell, Geraldine A ^d  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b FOUNDATION FOR BLOOD RESEARCH   (United States)

^c Clinigene Laboratories   (United States)

^d LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

Down syndrome; Genetic screening; Maternal serum screening; Prenatal diagnosis

Indexed keywords

ADULT; CLINICAL FEATURE; DOWN SYNDROME; FEMALE; FETUS; HUMAN; INFORMED CONSENT; LABORATORY DIAGNOSIS; PATIENT INFORMATION; PRACTICE GUIDELINE; PRENATAL SCREENING; REVIEW; SECOND TRIMESTER PREGNANCY; STANDARD;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; GENETIC SCREENING; HUMANS; PATIENT EDUCATION; PREGNANCY; PREGNANCY TRIMESTER, SECOND; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPECIMEN HANDLING;

EID: 20444448875     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000167808.96439.F3     Document Type: Review

References (28)

1. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Br J Obstet Gynaecol 1987;94:387-402.
2. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin. A J Med Screen 1998;5:115-119.
3. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-887.
4. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143-154.
5. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG, Watt H et al. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997;17:285-290.
6. Wald NJ, Densem JW, Smith D, Klee GG. Four-marker serum screening for Down's syndrome. Prenat Diagn 1994;14:707-716.
7. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1996;16: 927-929.
8. Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE. hCG and the free beta-subunit as screening tests for Down syndrome. Prenat Diagn 1998;18:235-245.
9. New York State Department of Health, Wadsworth Center, Laboratory Standards, Rev 12/2002 Available at: http://www.wadsworth.org/labcert/clep/ survey/ standardseff12605.pdf. Accessed May 2, 2005.
10. Hazardous Materials: Revision to Standards for Infectious Substances and Genetically Modified Micro-Organisms, US Environmental Protection Agency. Available at: http://www.epa.gov/fedrgstr/EPA-IMPACT/2001/January/Day-22/i92. htm. Accessed October 26, 2004.
11. NCCLS SC1-L Evaluation Protocols. Wayne, Pennsylvania: NCCLS Specialty Collection, 2003.
12. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
13. Haddow JE, Palomaki GE, Knight GJ, Canick JA. Prenatal Screening for Major Fetal Disorders: The Foundation for Blood Research Handbook, Volume II: Screening for Down Syndrome. 1998. Available at: www.fbr.org. Accessed October 26, 2004.
14. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16:1115-1119.
15. Hecht CA, Hook EB. Rates of Down syndrome at livebirth by one-year maternal age intervals in studies with apparent close to complete ascertainment in populations of European origin: a proposed revised rate schedule for use in genetic and prenatal screening. Am J Med Genet 1996;62:376-385.
16. Morris JK, Mutton DE, Alberman E. Revised estimates of maternal age specific live birth prevalence of Down's'syndrome in the absence of antenatal screening and selective termination. J Med Screen 2002;9:2-6.
17. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996;16:29-34.
18. Wald N, Cuckle H, Wu TS, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1991;98:905-908.
19. Estimating an individual's risk of having a fetus with open spina bifida, the value of repeat AFP testing. Report of the Fourth UK. Collaborative study on AFP in relation to neural tube defects. J Epidemiol Community Health 1982;36:87-95.
20. Cuckle H, Densem J, Wald NJ. Repeat maternal serum testing in multiple marker Down's syndrome screening programmes. Prenat Diagn 1994;14:603-607.
21. Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenat Diagn 2001;21:58-61.
22. Wald NJ, Hackshaw AK, George LM. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000;7:74-77.
23. Knight GJ, Palomaki GE. Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome. Clin Lab Med 2003;22:531-551.
24. College of American Pathologists. Available at: http://www.cap.org/apps/ docs/ laboratory_accreditation/Checklists/checklistftp.html. Accessed May 2, 2005.
25. Palomaki GE, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropoin. Prenat Diagn 1995;15:713-723.
26. Malone FD, D'Alton ME. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003;102:1066-1079.
27. Snijders RJ, Nobel P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine First Trimester Screening Group. Lancet 19981;352:343-346.
28. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341: 461-467.